title: International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
abstract: A multicenter study was sponsored by the International Atomic Energy Agency (IAEA) to assess the safety and efficacy of transarterial rhenium-188 ((188)Re) HDD lipiodol (radioconjugate to lipiodol using an HDD kit) in the treatment of unresectable hepatocellular carcinoma. During 5 years, 185 patients received at least 1 treatment of radioconjugate, and 51 were retreated. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated after a "scout" dose of radioconjugate. The total injected activity, including the scout dose during the first treatment, ranged from 21 to 364 mCi (mean, 108 mCi/4 GBq). Immediate and late side-effects were minimal. Tumor size could be evaluated in 88 patients. Among these patients, the objective response rate was 25%; stable disease was observed in 53% and tumor progression in 22%. With a median follow-up of 455 days, the estimated 12- and 24-month overall survival was 46% and 23%. This multicenter study shows that (188)Re lipiodol is a safe and cost-effective method to treat primary hepatocellular carcinoma via the transarterial route and requires further evaluation by treatment of greater numbers of patients.
authors.affiliation: Fundacion Santa Fe de Bogota, Bogota, Colombia.
authors.forename: Patricia
authors.initials: P
authors.lastname: Bernal
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
authors.forename: Janez
authors.initials: J
authors.lastname: Stare
authors.forename: Erdenechimeg
authors.initials: E
authors.lastname: Sereegotov
authors.forename: Felix X
authors.initials: FX
authors.lastname: Sundram
authors.forename: Ajay
authors.initials: A
authors.lastname: Kumar
authors.forename: Jae-Min
authors.initials: JM
authors.lastname: Jeong
authors.forename: Pawana
authors.initials: P
authors.lastname: Pusuwan
authors.forename: Chaitanya
authors.initials: C
authors.lastname: Divgi
authors.forename: Pat
authors.initials: P
authors.lastname: Zanzonico
authors.forename: Gaj
authors.initials: G
authors.lastname: Vidmar
authors.forename: John
authors.initials: J
authors.lastname: Buscombe
authors.forename: Trinh Thi Minh
authors.initials: TT
authors.lastname: Chau
authors.forename: Maung Maung
authors.initials: MM
authors.lastname: Saw
authors.forename: Shaoliang
authors.initials: S
authors.lastname: Chen
authors.forename: Ruben
authors.initials: R
authors.lastname: Ogbac
authors.forename: Maurizio
authors.initials: M
authors.lastname: Dondi
authors.forename: Ajit Kumar
authors.initials: AK
authors.lastname: Padhy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007390:International Agencies; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009678:Nuclear Energy; D011379:Prognosis; D011868:Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D011880:Radiotherapy Planning, Computer-Assisted; D012211:Rhenium / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D011868:Radioisotopes; D012211:Rhenium; D007459:Iodized Oil